Myriad Genetics Blog Blog > Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why. Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why. September 16, 2022 Provider Blog Urology Prolaris: Your NEW ADT decision tool When it comes to treating NCCN intermediate- and high-risk prostate cancer, it can be challenging to know which patients could truly benefit from the use of ADT (Androgen Deprivation Therapy) + RT (Radiation Therapy). The Prolaris white paper tells our exclusive story of consistent data across our validation and utility studies; giving you confidence to choose Prolaris when you need to know which patients would have little to no benefit from ADT. Request Prolaris White Paper If for some reason you don’t receive the email with your white paper download, make sure to check your junk folder. Physician First Name Physician Last Name Email NPI Number SpecialtyPlease select... Urology Urologic Oncology Radiation Oncology Pathology Zip Code How can we help? Hidden Fields Google Account ID Web_Form_URL__c Google_Client_Id__c GCLID UTM Medium UTM Source UTM Campaign UTM Content UTM Term AE_Email AE_First_Name AE_Last_Name Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy. reCAPTCHA helps prevent automated form spam. The submit button will be disabled until you complete the CAPTCHA. Contact Information Learn how Prolaris can benefit your practice Order a Urologist Guide Order a Radiation Oncologist Guide